Table 3. . Most common grade 3/4 treatment-emergent adverse events (≥2% in the tumor-treating fields plus second-line chemotherapy arm).

System organ class/preferred term	TTFields plus second-line chemotherapy (n = 144); n (%)	Second-line chemotherapy alone (n = 60); n (%)
Patients with ≥1 grade 3/4 adverse event	70 (49)	20 (33)
Blood and lymphatic system disorders:	16 (11)	2 (3)
– Thrombocytopenia	10 (7)	1 (2)
– Lymphopenia	6 (4)	1 (2)
– Leukopenia	4 (3)	0
Gastrointestinal disorders	5 (3)	0
General disorders and administration site conditions:	12 (8)	4 (7)
– Fatigue	5 (3)	2 (3)
– Gait disturbance	3 (2)	1 (2)
Infections and infestations:	9 (6)	0
– Meningitis	3 (2)	0
Injury, poisoning and procedural complications:	7 (5)	2 (3)
– Fall	4 (3)	0
Metabolism and nutrition disorders	4 (3)	4 (7)
Musculoskeletal and connective tissue disorders	5 (3)	2 (3)
Nervous system disorders:	40 (28)	11 (18)
– Convulsion	8 (6)	2 (3)
– Hemiparesis	6 (4)	0
– Headache	5 (3)	2 (3)
– Cognitive disorder	4 (3)	1 (2)
– Neurological decompensation	3 (2)	1 (2)
Psychiatric disorders:	6 (4)	1 (2)
– Mental status changes	4 (3)	0
Vascular disorders	5 (3)	1 (2)

TTFields: Tumor-treating fields.